Cyclo Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1990-01-01
- Employees
- 8
- Market Cap
- -
- Introduction
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Cyclo Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05607615
- Locations
- 🇺🇸
Access Research Institute, Brooksville, Florida, United States
🇺🇸Tandem/Clincloud, LCC, Marrero, Louisiana, United States
🇺🇸Advanced Clinical Institute Inc, Neptune, New Jersey, United States
Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1
- Conditions
- Niemann-Pick Disease, Type C1
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Cyclo Therapeutics, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT04860960
- Locations
- 🇺🇸
Emory, Atlanta, Georgia, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸UPMC Children's Hospital, Pittsburgh, Pennsylvania, United States
Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann-Pick Disease Type C
- Conditions
- Niemann-Pick Disease, Type C1
- Interventions
- Drug: Hydroxypropyl-β-cyclodextrin
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Cyclo Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03893071
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's Disease
- Conditions
- Late Onset Alzheimer Disease
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- Cyclo Therapeutics, Inc.
- Registration Number
- NCT03624842
Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)
- Conditions
- Niemann-Pick Disease, Type C1
- Interventions
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Cyclo Therapeutics, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02939547
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States
Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients
- Conditions
- Niemann-Pick Disease, Type C1
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Cyclo Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02912793
- Locations
- 🇮🇱
Soroka Mc, Beer sheva, Rager Blvd, Israel
🇮🇱HaeMek MC, 'Afula, Israel
🇸🇪Karolinska Trial Alliance, Solna, Huddinge, Sweden